AMR Action Fund, a venture capital fund, led a $35m Series C funding round in BioVersys, a clinical stage, multi-asset Swiss pharmaceutical company. “BioVersys is developing antimicrobials that target some of the most menacing drug-resistant bacteria in the world today, and we are thrilled to welcome the company to our portfolio. The candidates in its pipeline have the potential to significantly improve care for patients suffering from intractable infections for which there are few, if any, effective treatments. We are eager to work with the BioVersys team to help bring these therapeutics to patients,” Martin Heidecker, AMR Action Fund Chief Investment Officer.